Skip to content

Advertisement

  • Review
  • Open Access

The clinical relevance of animal models in Sjögren’s syndrome: the interferon signature from mouse to man

Arthritis Research & Therapy201517:172

https://doi.org/10.1186/s13075-015-0678-2

©  Maria et al. 2015

  • Published:

Abstract

Mouse models have been widely used to elucidate the pathogenic mechanisms of human diseases. The advantages of using these models include the ability to study different stages of the disease with particular respect to specific target organs, to focus on the role of specific pathogenic factors and to investigate the effect of possible therapeutic interventions. Sjögren’s syndrome (SS) is a systemic autoimmune disease, characterised by lymphocytic infiltrates in the salivary and lacrimal glands. To date, effective therapy is not available and treatment has been mainly symptomatic. Ongoing studies in murine models are aimed at developing more effective and targeted therapies in SS. The heterogeneity of SS will most probably benefit from optimising therapies, tailored to specific subgroups of the disease. In this review, we provide our perspective on the importance of subdividing SS patients according to their interferon signature, and recommend choosing appropriate mouse models for interferon-positive and interferon-negative SS subtypes. Murine models better resembling human-disease phenotypes will be essential in this endeavour.

Keywords

  • Systemic Lupus Erythematosus
  • Salivary Gland
  • Lacrimal Gland
  • Belimumab
  • Sialadenitis

Introduction to Sjögren’s syndrome

Sjögren’s syndrome (SS) is a systemic autoimmune disease characterised by lymphocytic infiltrates in salivary and lacrimal glands, sialadenitis and dacryoadenitis respectively. The disease can occur alone − primary Sjögren’s syndrome (pSS) − or together with other systemic autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis or rheumatoid arthritis − secondary SS. The prevalence of pSS is estimated to be between 0.05 and 1%, with a ninefold predominance in females. Characteristic symptoms are dry eyes (keratoconjunctivitis sicca) and mouth (xerostomia), with frequent presence of multiple extraglandular manifestations, such as vasculitis, severe fatigue and multiorgan involvement [1–3]. At present, no common evidence-based intervention therapy is available and treatment is mainly symptomatic. Thus, further unravelling the pathophysiology of pSS is essential for finding novel biomarkers and identifying new treatment targets.

Murine models are a sophisticated way to model complex pathogenic mechanisms for diseases such as SS, despite discrepancies in the immune system between human and mouse [4]. These models provide the opportunity to manipulate disease processes and look at multiple organs in depth during the early disease state as well as disease progression, which is particularly difficult to achieve in humans but is essential in developing new therapeutic strategies. Recently, an extensive update on SS-like murine-models was published in this journal [5].

Here we focus on the present knowledge of the pathogenesis of human pSS with special regard to the interferon (IFN) signature. As IFN type I is a suggested key pathogenic factor, we discuss how the currently used mouse models fit with subdividing patients into IFN-positive and IFN-negative subgroups. Taking this subdivision as a starting point we also recapitulate relevant disease features and interventional studies in the nonobese diabetic (NOD) mouse model, which is the most commonly used SS mouse model.

Sjögren’s syndrome: from man to mouse

Over the past decade, vast evidence for a role of IFN type I in the pathogenesis of pSS has emerged. We and others have described the presence of an IFN type I signature, assessed as upregulation of a distinct set of IFN type I inducible genes [6–12]. We describe the prevalence of the systemic IFN type I signature in over one-half of pSS patients (referred to as IFN-positive pSS), identifying a subgroup of patients with higher European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores, presence of anti-Sjögren’s syndrome-associated autoantigen SSA (Ro52 and Ro60) and/or anti-Sjögren’s syndrome-associated autoantigen SSB (La) autoantibodies, higher immunoglobulin (Ig) G and B-cell activating factor (BAFF) levels, and lower C3 complement levels [10]. The abundant presence of autoantibodies leading to circulating immune complexes (ICs) is thought to be the main trigger inducing the IFN signature in pSS and SLE [13].

In addition to IFN type I, novel evidence indicates IFN activation in SS glands to be partly attributed to IFN type II activity (IFNγ) [14]. Whether this also holds true for systemic IFN activation in pSS remains to be established. A recent study in SLE, however, revealed distinct systemic type I and type II signatures [15]. Fig. 1 depicts the multifactorial pathogenesis of pSS, where IFNs are centred as the main culprits in the self-amplifying pathogenic loop. Better understanding of these distinct IFN pathways is crucial in selective therapeutic targeting.
Fig. 1
Fig. 1

Multifactorial pathogenesis of primary Sjögren’s syndrome: interferons as culprits in the self-amplifying pathogenic loop. A damage trigger such as stress or infection leads to accumulating apoptotic debris, inducing rapid interferon (IFN) type I production by plasmacytoid dendritic cells (pDCs). IFN type I then binds to IFNα,β receptor (IFNAR) on adjacent target cells, which induces an IFN signature and IFN-primed mature effector cells, amongst others, by perpetuating the TLR7 pathway in autoreactive plasma cells as well as self-amplification in the pDCs. TLR7 upregulation in autoreactive plasma cells increases RNA-associated autoantibody production (SSA/Ro52, SSA/Ro60 and SSB/La). These RNA-associated autoantibodies form immune complexes together with self-apoptotic debris, further triggering the TLR7 pathway. Prolonged inflammation can lead to exhaustion of the complement system with decreased complement-mediated solubilisation and further accumulation of immune complexes. Neutrophils can cause further tissue damage by forming neutrophil extracellular traps, these netting neutrophils also being potent inducers of IFN type I production. Autoantibodies induce netting of IFN-primed neutrophils, further amplifying the loop. IFN-primed dendritic cells (DCs) activate T cells, as well as natural killer and natural killer T cells (data not shown), to produce vast amounts of IFN type II (IFNγ). Although TLRs are widely considered the usual suspects in autoimmune pathophysiology, recently the cytoplasmic RIG-I-like family of helicases (RLHs), RIG-I (DDX58) and MDA5 (IFIH1) have been gaining the spotlight as co-conspirators. Evidence points towards a collaborative effort between TLRs and RLHs, together enhancing inappropriate self-recognition and sustained IFN overactivation. IFIH1 upregulation has been identified in IFN-positive pDCs of primary Sjögren’s syndrome patients (unpublished data), as previously in glands of Sjögren’s syndrome-like (C57BL/6.NOD-Aec1Aec2) mice [61]. This IFN-driven pathogenic loop in primary Sjögren’s syndrome, in part driven by aberrant sensing of nucleic acids, can potentially lead to functional decline or even loss of function in target tissues. APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor; IL, interleukin; MDA5, melanoma differentiation-associated protein 5; MHC, major histocompatibility complex; RIG-I, retinoic acid-inducible gene 1; Th17, T-helper type 17; TLR, Toll-like receptor; Treg, regulatory T cells

Here we provide our perspective on the importance of subdividing pSS patients according to their IFN signature. To better resemble the human situation we will need to find models best fitting our subdivision, where one can be used as an IFN-negative model and the other, possibly accelerated by triggering the IFN system, can be used as its IFN-positive counterpart.

Interferon-related murine models as interferon-positive Sjögren’s syndrome

As IFNs play an eminent role in human pSS pathogenesis, we studied the NOD mouse model for the presence of systemic IFN activation and found no indication for the presence of a systemic IFN signature (McGuiness B, Beumer W and colleagues, unpublished work). We therefore suggest the NOD mouse to be systemically IFN-negative, and set out to look at some previous studies in murine models for a possible IFN-positive counterpart. Many systemic autoimmune models used for SLE, amongst other diseases, extensively direct their attention to IFNs and their role in autoimmune development [13, 16–18]. Here we highlight existing autoimmune murine models which in our opinion are models to be revisited for potential SS-like disease.

Interferon-inducible models in murine autoimmunity

External triggering of the IFN system in order to mimic systemic IFN overactivation is an approach often used in autoimmune-prone mice. Interestingly, the group of Deshmukh and colleagues applied this strategy to the lupus-prone New Zealand Black/White F1 mouse strain to study SS-like disease. After treatment of the mice with Toll-like receptor (TLR)-3 agonist poly(I:C), chronic systemic activation accelerated sialadenitis [19]. Interestingly, in addition to TLR3, poly(I:C) also engages the nucleic acid sensors retinoic acid-inducible gene I (RIG-I; DDX58) and melanoma differentiation associated antigen 5 (MDA5; IFIH1). These retinoic acid-inducible gene-like helicases have recently been suggested to collaborate with endosomal TLRs in amplifying IFN overactivation (see Fig. 1) [20–22], and thus might also contribute to overactivation of IFN in the poly(I:C)-treated mice. Retinoic acid-inducible gene-like helicases might be relevant therapeutic targets.

New Zealand Mixed (NZM) 2758 mice were additionally demonstrated to develop SS-like disease, after prior triggering of innate immunity by alum and induction of antibodies by immunisation with Ro52. This recent study focused on Ro52-induced salivary gland dysfunction and hypothesised that autoantibody deposition in the glands might be crucial to induce xerostomia and SS-like disease [23]. However, the role of IFNs in disease induction was not assessed.

Imbalanced Toll-like receptor signalling leads to murine autoimmunity

For the generation of autoantibodies by B cells and IC-mediated IFN production by plasmacytoid dendritic cells, myeloid differentiation primary response gene 88 (MyD88)-dependent endosomal TLR7 and TLR9 are crucial. Nucleic acid-sensing TLRs such as TLR3, TLR7, TLR8 and TLR9 are located in intracellular endosomal compartments, consequently minimising possible exposure to self-antigens [24]. Intriguingly, our group recently found that the TLR7 pathway was upregulated in peripheral blood cells of IFN-positive pSS, whereas TLR9 was not (NI Maria and colleagues, unpublished work). A similar imbalance in TLRs was observed in murine lupus models. Opposing effects were described for TLR7 and TLR9: deletion of TLR7 limited autoimmunity, whereas TLR9 deletion paradoxically exacerbated disease. TLR7 deletion prevented RNA-associated antibody formation, whereas TLR9 deletion resulted in increased systemic inflammation and IC-induced glomerulonephritis [18]. That controlling TLR7 expression is essential in restricting autoimmunity already became clear when TLR7 gene duplication was demonstrated to be the sole requirement for accelerated autoimmunity in B6.Yaa mice. A substantial TLR7 increase even caused fatal acute inflammatory pathology and extensive dendritic cell dysregulation [16]. This mouse model, portraying the Yaa phenotype (TLR7 gene duplication; BXSB/MpJ-Yaa), was recently described to develop autoimmune dacryoadenitis in a study focusing on SS-like features [25], showing ample reason for revisiting the herein-mentioned autoimmune models for SS.

The imbalance in endosomal TLRs, which results in much more prominent lupus-like disease compared with wild-type (WT) mice, was also recently shown using mice deficient in TLR8 and/or TLR9. TLR8 deficient mice (B6.TLR8−/−) and particularly double TLR8/9-deficient mice (B6.TLR8/9−/−) displayed marked induction of TLR7, which was associated with more severe disease. This study concludes that both TLR8 and TLR9 act together in controlling TLR7 function, TLR8 particularly controlling TLR7 function in dendritic cells and TLR9 restraining TLR7 response in B cells [17].

Other potential TLR-related models to be revisited are reviewed elsewhere [13], elaborating on possibilities for exacerbated renal disease in TLR9−/− versus reduced disease in their TLR7−/− counterpart. TLR9-deficient autoreactive B cells no longer undergo class switching to pathogenic immunoglobulin isotypes (IgG2a and IgG2b), these TLR9−/− mice having significantly smaller IgG deposits in the glomeruli and a prolonged survival compared with their TLR9 sufficient littermates. In contrast, TLR7-deficient mice no longer produce RNA-specific autoantibodies, developing less severe clinical disease than their TLR7 sufficient littermates [13].

Further investigating this imbalanced endosomal TLR signalling in IFN-driven pSS is warranted because most studies focus on SLE. The above mentioned murine models will be crucial in this endeavour, as the tight regulation of TLR7 is preventing autoreactivity leading to autoimmunity.

Toll-like receptor inhibitors in interferon-related autoimmunity

The antimalarial agent hydroxychloroquine has long been considered an effective treatment for SLE and is frequently used for pSS. Chloroquines are said to block TLR7/9 activation either by preventing acidification and maturation of the endosomes or by interacting with nucleic acids and thereby preventing TLR triggering. The exact mechanisms and effects of chloroquines remain controversial (reviewed in [24]), and the effect of other TLR-blocking agents needs to be evaluated. In fact, a recent clinical trial evaluating the efficacy of hydroxychloroquine for the main symptoms of pSS concluded that 24 weeks of treatment with hydroxychloroquine did not improve symptoms compared with placebo. As the authors conclude, further studies are indeed warranted to determine longer-term outcomes of hydroxychloroquine use [26].

In a recent study, New Zealand Black/White F1 mice were treated with a TLR7/8/9 antagonist. Treated mice had lower serum autoantibody levels, reduction in proteinuria and kidney histopathology compared with their untreated counterparts [27]. Interestingly, small-molecule dual TLR7/9 antagonists are currently being tested in SLE patients; however, selective TLR7 inhibition might be a more promising approach and should, in our opinion, be evaluated in SS-like murine models for therapeutic efficacy.

Targeting interferons and the IFNα,β receptor

The IFN type I family of cytokines comprises 17 subtypes, all signalling through a common receptor, the IFNα,β receptor (IFNAR). Blocking one single subtype with specific monoclonal antibodies has not shown the promising results anticipated in SLE trials, thus directly blocking the IFNAR might prove more beneficial. This approach is supported by a study showing that deletion of Ifnar1 prevented severe disease in at least two lupus-prone strains. Interestingly, monoclonal antibodies against human IFNAR are currently tested for effectivity in SLE and systemic sclerosis [28, 29]. Recently, B6.IFNAR−/− mice and WT mice triggered with IFN-inducing poly(I:C) were tested for salivary gland hypofunction. Loss of glandular function was evident in WT mice and limited in IFNAR−/− mice, thus indicating a crucial role for IFN type I in xerostomia [30]. This observation points towards possible therapeutically beneficial effects in blocking the IFNAR in pSS.

Type I and type II IFNs signal via different receptors but share overlapping patterns of activated genes downstream. A recent study in human salivary gland tissue provided evidence that IFN type II (IFNγ) also contributes to the IFN signature in SS glands, and therefore the role of IFNγ needs to be further investigated in humans and mice. Interestingly, Ro60 peptide-immunised Balb/c mice significantly developed increased levels of IFNγ which correlated to decreased salivary flow [31], but the effect of increased IFNγ on a systemic IFN signature remains to be analysed.

Autoantibodies and the BAFF/APRIL system in murine autoimmunity

IFN type I itself has vast effects on B-cell survival, possibly perpetuating the pathogenic loop. IFNs induce BAFF and a proliferation inducing ligand (APRIL) expression in monocytes, thereby contributing to antibody-producing plasma cell survival resulting in prolonged pathogenic autoantibody production. This further triggers IFN signalling as well as increased IC deposition in target tissues leading to chronic inflammation, damage and, ultimately, loss of function [32]. A recent study looking into the necessity of individual BAFF receptors BCMA, TACI and BR3 in receptor-deficient NZM 2328 mice concluded that any single BAFF receptor could be dispensable for lupus development in their model [33]. An earlier study by the same group however, found that BAFF-deficient NZM 2328 mice were largely spared from clinically overt disease. These mice only showed serological autoimmunity and renal pathology, whereas severe proteinuria and mortality were greatly reduced. Blocking BAFF might thus not fully reverse or eliminate underlying pathology, but seemingly leads to substantial clinical improvement in murine autoimmunity [34].

The study by Mackay and colleagues illustrates that our view on revisiting lupus-prone mouse models for SS pathology is a rewarding approach. In BAFF transgenic mice, considered a model for SLE, they observed SS-like disease characterised by severe sialadenitis, decreased saliva production and destruction of submandibular glands [35].

Supporting an important role for autoantibodies in pSS is a recent study performed in mice lacking the SLE and pSS autoantigen Ro52/TRIM21. After local damage induction by ear tagging, Ro52/TRIM21−/− mice develop a lupus-like phenotype. Ro52/TRIM21 interacts with IFN regulatory factors that play a role in tightly regulating IFN signalling. In these mice, cellular damage drives pathology via potential triggering of endosomal TLRs through enhanced IFN production [36]. Ro52-targeted autoantibodies produced by autoreactive B cells might be interfering with the important regulatory role of Ro52/TRIM21 in maintaining balanced IFN signalling.

Biologicals targeting the BAFF/APRIL system

Observations in lupus-prone mice led to rapid development of biologicals interfering with the BAFF/APRIL system such as belimumab (anti-BAFF) and atacicept (dual BAFF/APRIL inhibitor) [37]. Treatment of mice with rapidly progressive glomerulosclerosis in both early and late stages of disease with BAFF-Ig or TACI-Ig revealed that selective BAFF blockade was sufficient to both prevent disease development and progression. This led to the conclusion that both treatments were equally effective in retaining remission by prolonged B-cell depletion and a decrease in inflammatory response to renal IC deposition [38]. However, when disease was accelerated by IFNs, BAFF blockade only proved beneficial in the initiation phase and did not prevent progression once autoantibodies were present. These biologicals might not be sufficiently effective in later disease stages in autoantibody-positive patients and additional therapies targeting the pathways activated by IFN might be essential additives. Presently, belimumab is tested in human pSS, showing encouraging results. The belimumab in patients with pSS BELISS trials justify future studies with the BAFF-targeting drug in the autoantibody-positive subset of pSS [39, 40].

The nonobese diabetic mouse model as interferon-negative Sjögren’s syndrome

Nonobese diabetic and NOD-derived strains as spontaneous models for Sjögren’s syndrome

Apart from spontaneously developing diabetes, female NOD mice recapitulate typical SS-like symptoms such as decreased salivary flow and lymphocytic infiltrates in salivary glands [41, 42]. In contrast to inducible models for autoimmunity, NOD mice follow a pattern of initial morphological changes in the salivary glands prior to the onset of focal infiltration and manifestation of clinical symptoms at about 16 weeks of age [43, 44]. Furthermore, the disease profile in NOD mice resembles human SS concerning composition of infiltrates in salivary glands and partially in terms of the autoantibody profile [45]. Additionally, NOD mice develop lymphocytic infiltrates in the lacrimal glands and interestingly this dacryoadenitis develops more frequently in males. Microarray analysis on lacrimal glands of male NODs resulted in the identification of cathepsins as candidate biomarkers for SS [46, 47]. Initial infiltrating immune cells were found to be responsible for this increased cathepsin expression, thereby initiating lacrimal gland remodelling and degradation [48]. Interestingly, cathepsin expression increased in parallel with proinflammatory cytokines during autoimmune development in the male NODs [46]. In general, however, studies on lacrimal glands in NOD mice are rare and truly deserve more attention.

Autoimmune manifestations in NOD mice develop through a complex interplay of several factors composed of genetic predisposition and intrinsic immune dysfunctions which manifest under the influence of environmental conditions [49]. NOD mice develop diabetes in a major histocompatibility complex (MHC) class II-dependent manner prior to autoimmune exocrinopathy. Changing the MHC class II haplotype can protect NOD mice from developing diabetes but not SS-like disease, and can affect the severity of sialadenitis [50, 51]. Association of SS with genes encoding for human leukocyte antigen has been reported [52], and thus indicates the importance of the MHC haplotype.

Although T cells are the dominant type of lymphocytes found in the infiltrates, SS is thought to predominantly be a B-cell-mediated disease. NOD-Igμ null mice, which lack functional B cells, show the typical lymphocytic infiltrations in the salivary glands but do not develop hyposalivation until transfer of purified human SS-IgG or parental NOD-IgG, suggesting a crucial role for antibodies in an overt clinical stage of the disease rather than the initial phase of lymphocyte infiltration [53].

Transient depletion of regulatory T cells in NOD mice (performed at the age of 10 days) showed an accelerating effect on sialadenitis, while depletion in older mice did not influence sialadenitis [54]. Moreover, depletion of regulatory T cells in B-cell-deficient NOD−/− mice reversed resistance to an autoimmune phenotype and increased both the presence and size of salivary gland infiltrations compared with WT NOD mice [55]. These findings underline the importance of a balanced regulatory-cell and effector-cell population in different stages of disease. Nevertheless, how depletion of regulatory T cells affects exocrine gland dysfunction remains to be established because the grade of infiltration does not correlate with actual dryness. This important point must be realised because there is also no correlation between gland function and grade of infiltration in humans. Studies combining analysis of gland function and infiltration pattern are therefore warranted.

The development of diabetes and SS-like disease in NOD mice is accepted to occur as two separate events, after identification of Idd3 (also termed autoimmune exocrinopathy 1, Aec1) and Idd5 (also termed autoimmune exocrinopathy 2, Aec2) as the genetic risk regions being sufficient for manifestation of exocrine dysfunction in NOD mice [56]. Introduction of Idd3 and Idd5 loci from NOD in the nonautoimmune prone C57BL/6 strain resulted in the so-called C57BL/6.NOD-Aec1Aec2 strain, which develops SS-like disease but not diabetes. Comparable with human SS, SS-like disease in C57BL/6.NOD-Aec1Aec2 mice is initiated by a preclinical silent phase before the onset of overt disease [57, 58]. A study comparing human SS parotid gland tissue with salivary glands of Aec2/Aec2 mice revealed common dysregulated pathways − associated with leukocyte recruitment and germinal centre formation [59] − underlining the relevance of the model for testing novel therapeutics.

The interferon signature in NOD and NOD-derived strains

As described above, upregulation of IFN inducible genes termed the IFN signature has been observed both in target tissue and systemically in pSS patients [10, 60]. However, it is important to realise that observations in salivary glands do not imply that an IFN signature is systemically present.

The comparison of salivary gland IFN signatures in murine SS-like disease and human SS has been reviewed recently and clearly reveals expression of IFN type I induced genes in human pSS and NOD salivary glands [61, 62]. Interestingly, microarray analysis of male NOD lacrimal glands did not reveal increased IFN type I expression [46]. However, it is debatable whether data from murine glands can be compared with human peripheral blood studies. It is thus peculiar that most murine SS-like studies are focused on the IFN signature in the exocrine glands, fully disregarding the systemic aspect of the disease. We evaluated the gene expression patterns of NOD monocytes at various time points of disease development and found no evidence for systemic IFN type I activation (McGuiness B, Beumer W and colleagues, unpublished work). Hence, it should be mentioned that studies in human pSS simultaneously analysing the IFN signature in salivary glands and peripheral blood are still lacking. Therefore, there may well be pSS patients with local IFN type I activation in the glands but lacking systemic IFN type I activity, similar to NOD mice.

The pathogenic effect of IFN type I was assessed in C57BL/6.NOD-Aec1Aec2 mice deficient for Ifnar1 (B6.Aec1Aec2Ifnr1 −/− ) and thus unable to respond to IFN type I-mediated signalling [63]. B6.Aec1Aec2Ifnr1 −/− mice did not upregulate IFN-responsive genes in the submandibular glands in comparison with their WT counterparts, although only a limited number of targets were tested in this study. Most strikingly, these mice were protected from salivary gland dysfunction and showed reduced infiltration in salivary and lacrimal glands, even though they still generated a robust systemic autoantibody response. Taken together, these findings support the hypothesis that systemic and local IFN activation can occur as two separate events.

Although type I IFNs were initially thought to be the driving force for the IFN signature, both IFN type I and type II activity were detected in human pSS salivary gland biopsies [14], while in pSS a contribution of type II to the systemic IFN signature remains to be established. In submandibular glands of NOD mice it has clearly been demonstrated that IFN type II/IFNγ participates in the early onset of SS-like disease. NOD.IFNγ −/− and NOD.IFN-γR −/− mice fail to develop sialadenitis, although retaining lymphocytic infiltrates in the lacrimal glands [64]. Nevertheless, to date these findings remain limited to local similarities. Thus, although there are many overlapping features between human pSS and NOD mice, evidence for a systemic IFN type I signature as observed in more than 50% of the human pSS patients is lacking in NOD mice. We conclude that NOD and NOD-derived strains rather represent the subset of systemically IFN-negative SS patients, and could contribute significantly to insights into the pathogenesis of IFN-negative pSS patients.

Interventional studies in NOD and NOD-derived strains

Over the past years, several intervention studies have been performed on NOD or NOD-derived models, most of them using C57BL/6.NOD-Aec1Aec2 as a model for SS. Owing to space limitations, we selected from the large number of studies those that were tested in clinical trials or are in our view interesting candidates for translation into clinics.

Development of malignant lymphomas is a risk in pSS and therefore studies on mechanisms of malignant transformation are important. Lymphoid structure formation was found to be predictive for lymphoma development in human pSS [65]. To evaluate the inhibitory effect on lymphoid structure formation in exocrine glands of NOD mice, blockage of the lymphotoxin-beta receptor (LTBR) pathway by injection of LTBR-Ig was performed. LTBR blockage ablated lymphoid structures and reduced salivary gland tissue degeneration and lacrimal gland pathology, whereas salivary flow was partially restored [66, 67]. Nevertheless, injection of LTBR-Ig was performed in an early disease stage, and thus the effect on disease progression when administered in a late, overt disease phase remains to be tested.

The manipulation of co-stimulatory mechanisms by local gene therapy gave less conclusive results. Attempts to inhibit CD40 ligation in NOD mice did not alter SS-like disease at all [68], whereas CTLA-4-IgG expression in C57BL/6.NOD-Aec1Aec2 mice improved sialadenitis and salivary gland function [69]. At present, CTLA-4-IgG is being tested in clinical trials.

Several gene therapy-based studies targeting different SS-related cytokines were performed. In C57BL/6.NOD-Aec1Aec2 mice, targeting of interleukin (IL)-17 production by T-helper (Th) 17 cells locally in the salivary glands led to improved SS-like disease, independent of the disease state at administration [70]. Accordingly, systemically administered gene therapy using IL-27 to inhibit Th17 activity was performed in C57BL/6.NOD-Aec1Aec2 mice in early and advanced disease stages. The treatment did not alter lymphocytic infiltration but resulted in less severe clinical disease manifestation [71]. Overall, targeting Th17 networks might be a useful treatment option.

Recently the role of the cytokine IL-7, elevated in human-SS, has been analysed using C57BL/6.NOD-Aec1Aec2 mice. IL-7 was found to enhance the Th1 response and to promote the development of SS-like disease, whereas IL-7 blockade had a disease-ameliorating effect. Furthermore, IL-7 was found to influence Th1 responses via IFNγ activation [72]. Interestingly, IL-7 and TLR7 seem to act synergistically on T-cell and B-cell activation. Considering the importance of TLR7 activation in autoimmunity, IL-7 should be considered a future candidate for intervention studies [73]. Besides TLR7, TLR9 seems to be involved in the pathogenesis of SS-like disease in NOD mice. Activation of TLR9-dependent p38 mitogen-activated protein kinase was recently found to occur in an early disease state [74]. However, agonistic TLR9 treatment that activated the alternative nuclear factor-κB pathway increased salivary flow [75]. These findings support a crucial role for the TLR7/9 balance, where increased TLR9 signalling potentially salvages autoimmunity whilst a tilt towards TLR7 signalling actually exacerbates autoimmunity.

Taking these results together, it is important to note that the stage of SS-like disease in NOD mouse models strongly influences the outcome of different therapeutic interventions. The majority of treatments tested in mice were performed at an early disease stage. Intervening when overt disease is present in relevant animal models is required before these approaches are applicable in humans. Besides, human SS is mostly diagnosed in an overt phase.

Perspectives: from mouse to man

When drawing conclusions from mouse models for clinical relevance in humans, a proper understanding of both the similarities and differences in immune function between mouse and man remains crucial for adequate interpretation of mouse studies [4]. There is ongoing controversy when using murine models regarding appropriate extrapolation of obtained knowledge into a clinical setting. We therefore propose the best strategy to be a back and forth interplay between mice and men. Revisiting existing mouse models in a more disease-related way certainly might help to elucidate underrated aspects of the disease. In particular, lupus-prone models that can be used for SS might reveal novel insights into SS pathogenesis. Here we aimed to highlight this approach, looping the circle from mouse to man and back (see Fig. 2).
Fig. 2
Fig. 2

Primary Sjögren’s syndrome: a back and forth interplay from mouse to man. To investigate the heterogeneous and complex pathogenesis of primary Sjögren’s syndrome (pSS), murine models such as nonobese diabetic (NOD) or NOD-derived mice are indispensable. Knowledge-based implementation derived from mouse models is commonly implemented into human studies and potential clinical trials. As the heterogeneity of patients is often underestimated, we propose a back and forth interplay of knowledge between mouse and man, looping the circle from man to mouse and back. Hereby, models will further be improved to better resemble specific aspects of human disease, essential for both therapeutic development and outcome prediction. An important step will be to compare common deregulated pathways in both mouse and man to address therapeutic manipulations, by isolating whole blood/peripheral blood mononuclear cells (PBMCs) or extracting target tissue biopsies from salivary and lacrimal glands. Patient selection and subgrouping according to their interferon (IFN) signatures, into IFN-positive and IFN-negative subgroups, will require separate mouse models per subgroup. As the NOD mouse most probably represents the subset of systemically IFN-negative patients, we here propose the NOD model revisited: TLR7-induced systemic IFN signature in the NOD mouse as the IFN-positive counterpart, by topical application of the TLR-agonist imiquimod. Furthermore, comparing equal compartments in both subgroups of mice and men will give new insights into both the similarities and differences. Mouse models will remain crucial for preclinical exploration studies and will need continued revisiting and refining. TLR, Toll-like receptor

As SS in humans is very heterogeneous, multiple animal models are necessary to fully elucidate disease pathogeneses. Subtyping disease according to the prominent pathogenic player IFN, according to the IFN signature, is therefore a crucial first step. We highly recommend choosing appropriate mouse models for both IFN-negative and IFN-positive disease subtypes in future studies. In particular, we suggest NOD as a model for systemically IFN-negative SS. Recently, evidence for distinct roles of IFN type II and type III in autoimmunity has emerged [14, 15, 76], probably making subtyping even more complex in the near future but also much more effective for strategic therapeutic targeting.

In terms of developing new approaches for therapeutic interventions, the TLR–IFN network is a promising target and warrants more in-depth investigation. The delicate balance between endosomal TLRs appears crucial to prevent autoimmunity, and a better understanding of these pathways and how they are balanced will provide insight into specific targeted therapies [77]. Interestingly, tackling TLR7 will have effects on both plasmacytoid dendritic cells and B cells simultaneously, and might prove beneficial by inhibiting multiple aspects of the disease with one compound. Whether TLR7 blockade alone or in combination therapies will prevent and/or ameliorate pSS pathogenesis remains to be investigated [13].

Conclusions

The heterogeneity of SS will most probably benefit from optimising therapies, tailored to specific subgroups of the disease. Here we provide our perspective on the importance of subdividing SS patients according to their IFN signature, and recommend choosing appropriate mouse models for IFN-positive and IFN-negative SS subtypes. Murine models better resembling human-disease phenotypes will be essential in this endeavour.

Several key messages can be obtained from this review:
  1. 1.

    Simultaneous histopathology and functional analysis of salivary and lacrimal glands in relevant mouse models will result in further insight into SS pathogenesis

     
  2. 2.

    Lupus-prone mouse models should be revisited for salivary and lacrimal gland pathology and dysfunction

     
  3. 3.

    A distinction between local and systemic presence of IFN activity is essential, because local IFN activation does not directly imply the presence of systemic IFN activation

     
  4. 4.

    Therapeutic interventions should be tested when overt disease is present in relevant animal models, because pSS is diagnosed in this phase in humans

     

Abbreviations

Aec: 

autoimmune exocrinopathy

APRIL: 

a proliferation inducing ligand

BAFF: 

B-cell activating factor

ESSDAI: 

European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index

IC: 

immune complex

IFN: 

interferon

IFNAR: 

IFNα,β receptor

Ig: 

immunoglobulin

IL: 

interleukin

LTBR: 

lymphotoxin-beta receptor

MHC: 

major histocompatibility complex

MyD88: 

myeloid differentiation primary response gene 88

NOD: 

nonobese diabetic mice

pSS: 

primary Sjögren’s syndrome

SLE: 

systemic lupus erythematosus

SS: 

Sjögren’s syndrome

Th: 

T-helper

TLR: 

Toll-like receptor

WT: 

wild type

Declarations

Acknowledgements

The authors are indebted to Ms Denise Nijdam for aid in illustration design. The authors thank S Gilbert and R Callewaert for careful revision of the manuscript. NIM and MAV have received financial support from the Dutch Arthritis Foundation (Reumafonds) and the Netherlands Organization for Scientific Research (NWO), PV has received financial support from the Faculty of Medicine and Dentistry at the University of Bergen and the Broegelmann Foundation. This research is (in part) within the framework of the Erasmus Postgraduate School Molecular Medicine.

Authors’ Affiliations

(1)
Department of Immunology, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
(2)
Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, N-5021 Bergen, Norway

References

  1. Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum. 1984;14:77–105.PubMedView ArticleGoogle Scholar
  2. Fox RI, Kang HI. Pathogenesis of Sjogren’s syndrome. Rheum Dis Clin North Am. 1992;18:517–38.PubMedGoogle Scholar
  3. Nguyen CQ, Peck AB. Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease. Ocul Surf. 2009;7:11–27.PubMed CentralPubMedView ArticleGoogle Scholar
  4. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–8.PubMedView ArticleGoogle Scholar
  5. Delaleu N, Nguyen CQ, Peck AB, Jonsson R. Sjogren’s syndrome: studying the disease in mice. Arthritis Res Ther. 2011;13:217.PubMed CentralPubMedView ArticleGoogle Scholar
  6. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjogren’s syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005;52:1185–95.PubMedView ArticleGoogle Scholar
  7. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren’s syndrome. Proc Natl Acad Sci U S A. 2006;103:2770–5.PubMed CentralPubMedView ArticleGoogle Scholar
  8. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjogren’s syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008;38:2024–33.PubMedView ArticleGoogle Scholar
  9. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, et al. Peripheral blood gene expression profiling in Sjogren’s syndrome. Genes Immun. 2009;10:285–96.PubMed CentralPubMedView ArticleGoogle Scholar
  10. Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren’s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72:728–35.PubMed CentralPubMedView ArticleGoogle Scholar
  11. Maria NI, Brkic Z, Waris M, van Helden-Meeuwsen CG, Heezen K, van de Merwe JP, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren’s syndrome. Ann Rheum Dis. 2014;73:1052–9.PubMed CentralPubMedView ArticleGoogle Scholar
  12. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren’s syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52:1534–44.PubMedView ArticleGoogle Scholar
  13. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823–35.PubMedView ArticleGoogle Scholar
  14. Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A. 2012;109:17609–14.PubMed CentralPubMedView ArticleGoogle Scholar
  15. Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014;66:1583–95.PubMed CentralPubMedView ArticleGoogle Scholar
  16. Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, Ward JM, et al. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity. 2007;27:801–10.PubMed CentralPubMedView ArticleGoogle Scholar
  17. Desnues B, Macedo AB, Roussel-Queval A, Bonnardel J, Henri S, Demaria O, et al. TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci U S A. 2014;111:1497–502.PubMed CentralPubMedView ArticleGoogle Scholar
  18. Jackson SW, Scharping NE, Kolhatkar NS, Khim S, Schwartz MA, Li QZ, et al. Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol. 2014;192:4525–32.PubMed CentralPubMedView ArticleGoogle Scholar
  19. Nandula SR, Scindia YM, Dey P, Bagavant H, Deshmukh US. Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjogren’s syndrome-like disease. Oral Dis. 2011;17:801–7.PubMed CentralPubMedView ArticleGoogle Scholar
  20. Szabo A, Rajnavolgyi E. Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral innate immune responses. Am J Clin Exp Immunol. 2013;2:195–207.PubMed CentralPubMedGoogle Scholar
  21. Szabo A, Magyarics Z, Pazmandi K, Gopcsa L, Rajnavolgyi E, Bacsi A. TLR ligands upregulate RIG-I expression in human plasmacytoid dendritic cells in a type I IFN-independent manner. Immunol Cell Biol. 2014;92:671–8.PubMedView ArticleGoogle Scholar
  22. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637–50.PubMedView ArticleGoogle Scholar
  23. Szczerba BM, Kaplonek P, Wolska N, Podsiadlowska A, Rybakowska PD, Dey P et al. Interaction between innate immunity and Ro52-induced antibody causes Sjögren’s syndrome-like disorder in mice. Ann Rheum Dis. 2015. doi:2010.1136/annrheumdis-2014-206297.Google Scholar
  24. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–33.PubMedView ArticleGoogle Scholar
  25. Kosenda K, Ichii O, Otsuka S, Hashimoto Y, Kon Y. BXSB/MpJ-Yaa mice develop autoimmune dacryoadenitis with the appearance of inflammatory cell marker messenger RNAs in the lacrimal fluid. Clin Exp Ophthalmol. 2013;41:788–97.View ArticleGoogle Scholar
  26. Gottenberg JE, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312:249–58.PubMedView ArticleGoogle Scholar
  27. Zhu FG, Jiang W, Bhagat L, Wang D, Yu D, Tang JX, et al. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity. 2013;46:419–28.PubMedView ArticleGoogle Scholar
  28. Stohl W. Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2013;9:705–20.PubMedView ArticleGoogle Scholar
  29. Goldberg A, Geppert T, Schiopu E, Frech T, Hsu V, Simms RW, et al. Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16:R57.PubMed CentralPubMedView ArticleGoogle Scholar
  30. Nandula SR, Dey P, Corbin KL, Nunemaker CS, Bagavant H, Deshmukh US. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. J Oral Pathol Med. 2013;42:66–72.PubMed CentralPubMedView ArticleGoogle Scholar
  31. Yin H, Vosters JL, Roescher N, D’Souza A, Kurien BT, Tak PP, et al. Location of immunization and interferon-gamma are central to induction of salivary gland dysfunction in Ro60 peptide immunized model of Sjogren’s syndrome. PLoS One. 2011;6, e18003.PubMed CentralPubMedView ArticleGoogle Scholar
  32. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365–73.PubMedView ArticleGoogle Scholar
  33. Jacob CO, Yu N, Guo S, Jacob N, Quinn 3rd WJ, Sindhava V, et al. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum. 2013;65:1043–54.PubMed CentralPubMedView ArticleGoogle Scholar
  34. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006;177:2671–80.PubMed CentralPubMedView ArticleGoogle Scholar
  35. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest. 2002;109:59–68.PubMed CentralPubMedView ArticleGoogle Scholar
  36. Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana FJ, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med. 2009;206:1661–71.PubMed CentralPubMedView ArticleGoogle Scholar
  37. Boneparth A, Davidson A. B-cell activating factor targeted therapy and lupus. Arthritis Res Ther. 2012;14:S2.PubMed CentralPubMedView ArticleGoogle Scholar
  38. Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010;62:1457–68.PubMed CentralPubMedView ArticleGoogle Scholar
  39. Pontarini E, Fabris M, Quartuccio L, Cappeletti M, Calcaterra F, Roberto A, et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2015. doi: 10.1093.Google Scholar
  40. Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjogren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74:526–31.PubMedView ArticleGoogle Scholar
  41. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008;4551109–13.Google Scholar
  42. Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M, et al. NOD mouse model for Sjogren’s syndrome: lack of longitudinal stability. Oral Dis. 2006;12:566–72.PubMedView ArticleGoogle Scholar
  43. Cha S, van Blockland SC, Versnel MA, Homo-Delarche F, Nagashima H, Brayer J, et al. Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy. Exp Clin Immunogenet. 2001;18:143–60.PubMedView ArticleGoogle Scholar
  44. Roescher N, Lodde BM, Vosters JL, Tak PP, Catalan MA, Illei GG, et al. Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjogren’s syndrome. Oral Dis. 2012;18:96–106.PubMed CentralPubMedView ArticleGoogle Scholar
  45. Cha S, Peck AB, Humphreys-Beher MG. Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit Rev Oral Biol Med. 2002;13:5–16.PubMedView ArticleGoogle Scholar
  46. Li X, Wu K, Edman M, Schenke-Layland K, MacVeigh-Aloni M, Janga SR, et al. Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse. Invest Ophthalmol Vis Sci. 2010;51:5019–29.PubMed CentralPubMedView ArticleGoogle Scholar
  47. Hamm-Alvarez SF, Janga SR, Edman MC, Madrigal S, Shah M, Frousiakis SE, et al. Tear cathepsin S as a candidate biomarker for Sjogren’s syndrome. Arthritis Rheumatol. 2014;66:1872–81.PubMed CentralPubMedView ArticleGoogle Scholar
  48. Schenke-Layland K, Xie J, Magnusson M, Angelis E, Li X, Wu K, et al. Lymphocytic infiltration leads to degradation of lacrimal gland extracellular matrix structures in NOD mice exhibiting a Sjogren’s syndrome-like exocrinopathy. Exp Eye Res. 2010;90:223–37.PubMed CentralPubMedView ArticleGoogle Scholar
  49. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005;23:447–85.PubMedView ArticleGoogle Scholar
  50. Robinson CP, Yamachika S, Bounous DI, Brayer J, Jonsson R, Holmdahl R, et al. A novel NOD-derived murine model of primary Sjogren’s syndrome. Arthritis Rheum. 1998;41:150–6.PubMedView ArticleGoogle Scholar
  51. Lindqvist AK, Nakken B, Sundler M, Kjellen P, Jonsson R, Holmdahl R, et al. Influence on spontaneous tissue inflammation by the major histocompatibility complex region in the nonobese diabetic mouse. Scand J Immunol. 2005;61:119–27.PubMedView ArticleGoogle Scholar
  52. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome. Nat Genet. 2013;45:1284–92.PubMedView ArticleGoogle Scholar
  53. Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren’s syndrome. Proc Natl Acad Sci U S A. 1998;95:7538–43.PubMed CentralPubMedView ArticleGoogle Scholar
  54. Nakahara M, Nagayama Y, Ichikawa T, Yu L, Eisenbarth GS, Abiru N. The effect of regulatory T-cell depletion on the spectrum of organ-specific autoimmune diseases in nonobese diabetic mice at different ages. Autoimmunity. 2011;44:504–10.PubMedView ArticleGoogle Scholar
  55. Ellis JS, Wan X, Braley-Mullen H. Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice. Immunology. 2013;139:179–86.PubMed CentralPubMedView ArticleGoogle Scholar
  56. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren’s syndrome) on a healthy murine background. Arthritis Rheum. 2002;46:1390–8.PubMedView ArticleGoogle Scholar
  57. Delaleu N, Nguyen CQ, Tekle KM, Jonsson R, Peck AB. Transcriptional landscapes of emerging autoimmunity: transient aberrations in the targeted tissue’s extracellular milieu precede immune responses in Sjögren’s syndrome. Arthritis Res Ther. 2013;15:R174.PubMed CentralPubMedView ArticleGoogle Scholar
  58. Jonsson R, Theander E, Sjostrom B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjogren syndrome. JAMA. 2013;310:1854–5.PubMedView ArticleGoogle Scholar
  59. Horvath S, Nazmul-Hossain AN, Pollard RP, Kroese FG, Vissink A, Kallenberg CG, et al. Systems analysis of primary Sjogren’s syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model. Arthritis Res Ther. 2012;14:R238.PubMed CentralPubMedView ArticleGoogle Scholar
  60. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013;25:248–53.PubMedView ArticleGoogle Scholar
  61. Peck AB, Nguyen CQ. Transcriptome analysis of the interferon-signature defining the autoimmune process of Sjogren’s syndrome. Scand J Immunol. 2012;76:237–45.PubMed CentralPubMedView ArticleGoogle Scholar
  62. Nguyen CQ, Peck AB. The interferon-signature of Sjogren’s syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front Immunol. 2013;4:142.PubMed CentralPubMedView ArticleGoogle Scholar
  63. Szczerba BM, Rybakowska PD, Dey P, Payerhin KM, Peck AB, Bagavant H, et al. Type I interferon receptor deficiency prevents murine Sjogren’s syndrome. J Dent Res. 2013;92:444–9.PubMed CentralPubMedView ArticleGoogle Scholar
  64. Cha S, Brayer J, Gao J, Brown V, Killedar S, Yasunari U, et al. A dual role for interferon-gamma in the pathogenesis of Sjogren’s syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol. 2004;60:552–65.PubMedView ArticleGoogle Scholar
  65. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren’s syndrome. Ann Rheum Dis. 2011;70:1363–8.PubMed CentralPubMedView ArticleGoogle Scholar
  66. Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren’s syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther. 2009;11:R24.PubMed CentralPubMedView ArticleGoogle Scholar
  67. Fava RA, Kennedy SM, Wood SG, Bolstad AI, Bienkowska J, Papandile A, et al. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjogren’s syndrome. Arthritis Res Ther. 2011;13:R182.PubMed CentralPubMedView ArticleGoogle Scholar
  68. Roescher N, Vosters JL, Lai Z, Uede T, Tak PP, Chiorini JA. Local administration of soluble CD40:Fc to the salivary glands of non-obese diabetic mice does not ameliorate autoimmune inflammation. PLoS One. 2012;7, e51375.PubMed CentralPubMedView ArticleGoogle Scholar
  69. Yin H, Nguyen CQ, Samuni Y, Uede T, Peck AB, Chiorini JA. Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjogren’s syndrome. Arthritis Res Ther. 2012;14:R40.PubMed CentralPubMedView ArticleGoogle Scholar
  70. Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB. IL17: potential therapeutic target in Sjogren’s syndrome using adenovirus-mediated gene transfer. Lab Invest. 2011;91:54–62.PubMed CentralPubMedView ArticleGoogle Scholar
  71. Lee BH, Carcamo WC, Chiorini JA, Peck AB, Nguyen CQ. Gene therapy using IL-27 ameliorates Sjogren’s syndrome-like autoimmune exocrinopathy. Arthritis Res Ther. 2012;14:R172.PubMed CentralPubMedView ArticleGoogle Scholar
  72. Jin JO, Kawai T, Cha S, Yu Q. Interleukin-7 enhances the Th1 response to promote the development of Sjögren’s syndrome-like autoimmune exocrinopathy in mice. Arthritis Rheum. 2013;65:2132–42.PubMedView ArticleGoogle Scholar
  73. Bikker A, Kruize AA, van der Wurff-Jacobs KM, Peters RP, Kleinjan M, Redegeld F, et al. Interleukin-7 and Toll-like receptor 7 induce synergistic B cell and T cell activation. PLoS One. 2014;9, e94756.PubMed CentralPubMedView ArticleGoogle Scholar
  74. Shi H, Yu CQ, Xie LS, Wang ZJ, Zhang P, Zheng LY. Activation of TLR9-dependent p38MAPK pathway in the pathogenesis of primary Sjogren’s syndrome in NOD/Ltj mouse. J Oral Pathol Med. 2014. doi:10.1111/jop.12209.Google Scholar
  75. Gilboa-Geffen A, Wolf Y, Hanin G, Melamed-Book N, Pick M, Bennett ER, et al. Activation of the alternative NFkappaB pathway improves disease symptoms in a model of Sjogren’s syndrome. PLoS One. 2011;6, e28727.PubMed CentralPubMedView ArticleGoogle Scholar
  76. Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther. 2011;13:R88.PubMed CentralPubMedView ArticleGoogle Scholar
  77. Puig M, Tosh KW, Schramm LM, Grajkowska LT, Kirschman KD, Tami C, et al. TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo. J Leukoc Biol. 2012;91:147–58.PubMedView ArticleGoogle Scholar

Copyright

© Maria et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us